Athanasios Notopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Athanasios Notopoulos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Evangelia Zaromytidou
Nuclear Medicine Department, Hippokration General Hospital, 54642 Thessaloniki, Greece
2 shared publications - Anna Gotzamani-Psarrakou
Laboratory of Nuclear Medicine, AHEPA University Hospital of Thessaloniki, 54636 Thessaloniki, Greece
1 shared publication - Despoina Drivakou
Urogynecology Unit, 2nd Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, Hippokration General Hospital, 546 42 Thessaloniki, Greece
1 shared publication - Eleni Manthou
Diabetes Center, First Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece
1 shared publication - Georgios Dimakopoulos
BIOSTATS, Epirus Science and Technology Park Campus, University of Ioannina, 45110 Ioannina, Greece
1 shared publication - Ioannis Iakovou
AHEPA Hospital, Aristotle University, Thessaloniki, Greece
1 shared publication
Latest Publications
- Open Access
- 26 April 2024
- Published by IntechOpen
Thyroid Imaging Tests
Thyroid imaging tests provide more information about the thyroid gland’s size, shape, and function. After the thyroid blood tests which are the gold standard for the assessment of conditions like hypothyroidism or hyperthyroidism, imaging tests are recommended to establish a diagnosis. Although the diagnosis of hypothyroidism in itself is not an indication of thyroid imaging, thyroid radionuclide scanning may be useful in elucidating several pathophysiological aspects of hyperthyroidism and in determining the cause of abnormal thyroid function. This may be especially crucial in deciding whether a person will take thyroxine replacement therapy. However, it is important to recognize whether the cause of hypothyroidism is transient or drug-induced because this may require no treatment or only short-term thyroxine supplementation.
- 26 April 2024
- Published by IntechOpen
Open AccessThyroid Imaging Tests
Thyroid imaging tests provide more information about the thyroid gland’s size, shape, and function. After the thyroid blood tests which are the gold standard for the assessment of conditions like hypothyroidism or hyperthyroidism, imaging tests are recommended to establish a diagnosis. Although the diagnosis of hypothyroidism in itself is not an indication of thyroid imaging, thyroid radionuclide scanning may be useful in elucidating several pathophysiological aspects of hyperthyroidism and in determining the cause of abnormal thyroid function. This may be especially crucial in deciding whether a person will take thyroxine replacement therapy. However, it is important to recognize whether the cause of hypothyroidism is transient or drug-induced because this may require no treatment or only short-term thyroxine supplementation.
- Open Access
- 20 September 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (10) , 884
Vitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study
Older people are prone to frailness, present poor adherence to pharmacotherapy, and often have adverse drug effects. Therefore, it is important to develop effective and safe interventions to mitigate the burden of anxiety and depression disorders in this population. The aim of this study was to investigate the effect of vitamin D supplementation on the anxiety and depression status of elderly people with prediabetes. Participants were randomly assigned a weekly dose of vitamin D3 of 25,000 IU (n = 45, mean age 73.10 ± 7.16 years) or nothing (n = 45, mean age 74.03 ± 7.64 years), in addition to suggested lifestyle measures. The State-Trait Anxiety Inventory subscales (STAI-T and STAI-S) and the Patient Health Questionnaire-9 (PHQ-9) were used to evaluate anxiety and depression levels, respectively, at baseline, 6, and 12 months. A total of 92.68% of the participants in the vitamin D group and 97.14% of the controls exhibited vitamin D deficiency (p = 0.003) and 12 months (32.35 ± 7.77 vs. 44.97 ± 7.78, p < 0.001). The same pattern was evident for STAI-S scores at 6 (37.11 ± 7.88 vs. 43.20 ± 9.33, p = 0.003) and 12 months (32.59 ± 6.45 vs. 44.60 ± 9.53, p < 0.001). Supplemented participants demonstrated lower mean PHQ-9 scores compared to controls at 6 (15.69 ± 6.15 vs. 19.77 ± 8.96, p = 0.021) and 12 months (13.52 ± 5.01 vs. 20.20 ± 8.67, p < 0.001). Participants with deficiency and insufficiency at baseline experienced equal benefits of supplementation in terms of anxiety and depression scores. In conclusion, in a high-risk population, a weekly vitamin D supplementation scheme was effective in alleviating anxiety and depression symptoms. More studies are needed to elucidate the relevant mechanisms.
- 20 September 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (10) , 884
Open AccessVitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study
Older people are prone to frailness, present poor adherence to pharmacotherapy, and often have adverse drug effects. Therefore, it is important to develop effective and safe interventions to mitigate the burden of anxiety and depression disorders in this population. The aim of this study was to investigate the effect of vitamin D supplementation on the anxiety and depression status of elderly people with prediabetes. Participants were randomly assigned a weekly dose of vitamin D3 of 25,000 IU (n = 45, mean age 73.10 ± 7.16 years) or nothing (n = 45, mean age 74.03 ± 7.64 years), in addition to suggested lifestyle measures. The State-Trait Anxiety Inventory subscales (STAI-T and STAI-S) and the Patient Health Questionnaire-9 (PHQ-9) were used to evaluate anxiety and depression levels, respectively, at baseline, 6, and 12 months. A total of 92.68% of the participants in the vitamin D group and 97.14% of the controls exhibited vitamin D deficiency (p = 0.003) and 12 months (32.35 ± 7.77 vs. 44.97 ± 7.78, p < 0.001). The same pattern was evident for STAI-S scores at 6 (37.11 ± 7.88 vs. 43.20 ± 9.33, p = 0.003) and 12 months (32.59 ± 6.45 vs. 44.60 ± 9.53, p < 0.001). Supplemented participants demonstrated lower mean PHQ-9 scores compared to controls at 6 (15.69 ± 6.15 vs. 19.77 ± 8.96, p = 0.021) and 12 months (13.52 ± 5.01 vs. 20.20 ± 8.67, p < 0.001). Participants with deficiency and insufficiency at baseline experienced equal benefits of supplementation in terms of anxiety and depression scores. In conclusion, in a high-risk population, a weekly vitamin D supplementation scheme was effective in alleviating anxiety and depression symptoms. More studies are needed to elucidate the relevant mechanisms.